Allergan's Sanctura IP Appeal Turned Away By High Court
The U.S. Supreme Court on Monday refused to take up Allergan Inc.'s appeal of a ruling that invalidated patents covering the company's overactive bladder medication Sanctura XR, which Allergan had accused...To view the full article, register now.
Already a subscriber? Click here to view full article